 | |
| Type | Société Anonyme |
|---|---|
| Industry | Biopharmaceutical |
| Founded | Lausanne, Switzerland (1979) |
| Founder | Dr Rolland-Yves Mauvernay (1922-2017) |
| Headquarters | Lausanne, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | |
| Owner | Privately-held |
| Website | www.debiopharm.com |
Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. [1] It was founded in 1979 by Rolland-Yves Mauvernay.
Rolland-Yves Mauvernay founded Debiopharm in 1979 in Martigny, Switzerland. [2] In 1981, the Cytotech laboratory was created and after a few years it became Debio Recherche Pharmaceutique (R.P.), then Debiopharm Research & Manufacturing. [3] [4] Initially, the company worked on interferon and, in 1982, it began to focus on triptorelin, after having acquired the rights for its development from Tulane University. [5] Triptorelin is a Gonadotropin-releasing hormone agonist (GnRH agonist) that has been approved for several indications, including advanced prostate cancer and endometriosis. [6] [7] The first marketing authorization for this medication was obtained in France in 1986. [8]
In 1989, Debiopharm acquired the license for oxaliplatin, a diaminocyclohexane (DACH) platin, from Nagoya City University. The drug was first approved in Europe in 1996 and became a standard treatment in metastatic colorectal cancer. [9] Since launch, triptorelin and oxaliplatin have generated several billion dollars in revenue for the company. [10]
In 2004, after having occupied different premises in Lausanne, Debiopharm moved its headquarters to a new building: what became "Après-demain Forum" had been initially designed by architect Jean Tschumi as the headquarters commodity trading giant Andre and is a cultural property of national significance. [11]
In 2005, Debiopharm acquired the Canadian company H3 Pharma, rebranded Debiovision, to support the development and worldwide registration of its medicines. [12]
The company's business model relies on establishing partnerships and research agreements with other companies or universities to develop new molecules and run clinical trials before licensing them in case of success. It partnered for instance in 2009 with US-based MSM Protein Technologies to work on a new oncology treatment, [13] in 2011 with Yale University as part of an agreement to develop and commercialise medicine for autoimmune and inflammatory diseases, [14] in 2014 with German company Evotec to identify and develop compounds to treat a variety of cancers, [15] or with Canadian company Nobelex Biotech (also in 2014) to develop antibiotics targeting Neisseria gonorrhoeae and enteric species. [16]
In March 2021, Merck KGaA announced the acquisition of Debiopharm's xevinapant program in head and neck cancer for 900 million euros. [17]
Debiopharm is the Life Science division of the holding company Après-demain (litt. "The Day after Tomorrow") with three subsidiaries active in drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and investment (Debiopharm Innovation Fund): [18] [19]
Until 2020, the subsidiary Debiopharm Investment SA managed the group's asset management activities. [28] This subsidiary was merged and its former activities are now directly taken over by the holding company Après-demain SA. [28]
Debiopharm is known for the development of triptorelin and oxaliplatlin, two drugs that became standards of care for the treatment of various types of cancer and are listed on the World Health Organization's List of Essential Medicines. [29] [30]
Early-stage treatments being developed by Debiopharm are referred to by code names such as "Debio [+4 digit number]". [33] In 2020, Debiopharm signed a global license and research agreement with German biotech 3B Pharmaceuticals (3BP) to work on "Debio 0228", a treatment targeting the CAIX (Carbonic anhydrase 9) enzyme to fight the progression of cancer. [34] Other drug candidates under development include:
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.
The pharmaceutical industry discovers, develops, produces, and markets pharmaceutical drugs for the use as medications to be administered to patients, with the aim to cure and prevent diseases, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy using drug testing and marketing of drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020 and showed a compound annual growth rate (CAGR) of 1.8%.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication used to treat colorectal cancer. It is given by injection into a vein.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin-releasing hormone, repressing expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and invasive mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).
Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company, and a subsidiary of Otsuka Holdings, which focuses on developing cancer treatments. Taiho, headquartered in Tokyo, Japan, is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Onyx Pharmaceuticals Inc. has been a biopharmaceutical company headquartered in South San Francisco, California. The company developed and marketed medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. McCormick served as the chief scientific officer until 1998, while Kinsella was the firm's chairman. In 2009, the company acquired Proteolix, Inc., a private biotechnology company, for $276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx president and chief executive officer (CEO) Tony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal.
Incyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies, founded by Vivek Ramaswamy.
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
